Role of Cytochrome P450 Phenotyping in Cancer Treatment
Authors:
- 20 February 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (6) , 1053-1055
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous CortisolJournal of Clinical Oncology, 2005
- Dexamethasone as a probe for docetaxel clearanceCancer Chemotherapy and Pharmacology, 2004
- Population pharmacokinetics of weekly docetaxel in patients with advanced cancerBritish Journal of Clinical Pharmacology, 2003
- Genetic contribution to variable human CYP3A-mediated metabolismAdvanced Drug Delivery Reviews, 2002
- Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping StrategiesJournal of Clinical Oncology, 2002
- Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous CortisolJournal of Clinical Oncology, 2000
- Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probesPharmacogenetics, 2000
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?Journal of Clinical Oncology, 1998
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994